Williams, Christopher Kazu
  • Staff Research Associate, Pathology

  • Manager of the ADRC Tissue Core Resources

Williams, Christopher Kazu

Contact

UCLA Path & Lab Med
BOX 951732, 18-170B NPI
Los Angeles, CA 90095-1732
Phone:(310) 825-6191
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Publications (selected peer-reviewed publications)

    • Leonel Ampie, Winward Choy, Joseph D. DiDomenico, Jonathan D. Lamano, Christopher Kazu Williams, Kartik Kesavabhotla, Qinwen Mao, Orin Bloch. Clinical attributes and surgical outcomes of angiocentric gliomas. Journal of Clinical Neuroscience, 2016.
    • Magaki SD, Williams CK, Vinters HV. Glial function (and dysfunction) in the normal & ischemic brain. Neuropharmacology, 2017.
    • Shino D Magaki, MD; Zhaoyi Tang, BA; Spencer Tung, BS; Christopher K Williams; Darrick Lo, BS; William H Yong, MD; Negar Khanlou, MD; Harry V Vinters, MD. The effects of cerebral amyloid angiopathy on integrity of the blood brain. Neurobiology of Aging, 2017.
    • Guanxi Xiao1, Rosie Kumar, Jasmine Burguet, Yutaro Komuro, Visesha Kakarla1, Christopher K. Williams, Xinhai R. Zhang, Michal Macknicki, Andrew Brumm, Riki Kawaguchi, Harry V. Vinters, S. Thomas Carmichael, Leif A. Havton, Charlie DeCarli, Jason D. Hinman. Diet-induced obesity promotes white matter endothelial injury and signals to oligodendrocyte progenitor cells through CXCL5. Science Translational Medicine (publication in process).
    • Cepeda C, Oikonomou KD, Cummings D, Barry J, Yazon VW, Chen DT, Asai J, Williams CK, Vinters HV. Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations. J Neurosci Res. 2019 Dec;97(12):1624-1635. doi: 10.1002/jnr.24503. Epub 2019 Jul 28. PMID: 31353533; PMCID: PMC6801077.
    • Seidler PM, Boyer DR, Murray KA, Yang TP, Bentzel M, Sawaya MR, Rosenberg G, Cascio D, Williams CK, Newell KL, Ghetti B, DeTure MA, Dickson DW, Vinters HV, Eisenberg DS. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples. J Biol Chem. 2019 Nov 1;294(44):16451-16464. doi: 10.1074/jbc.RA119.009688. Epub 2019 Sep 19. PMID: 31537646; PMCID: PMC6827308.
    • Sangwan S, Sahay S, Murray KA, Morgan S, Guenther EL, Jiang L, Williams CK, Vinters HV, Goedert M, Eisenberg DS. Inhibition of synucleinopathic seeding by rationally designed inhibitors. Elife. 2020 Jan 2;9:e46775. doi: 10.7554/eLife.46775. PMID: 31895037; PMCID: PMC6977966.
    • Qin M, Wang L, Wu D, Williams CK, Xu D, Kranz E, Guo Q, Guan J, Vinters HV, Lee Y, Xie Y, Luo Y, Sun G, Sun X, He Z, Lu Y, Kamata M, Wen J, Chen ISY. Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates. Front Immunol. 2020 Jan 23;10:3132. doi: 10.3389/fimmu.2019.03132. PMID: 32047498; PMCID: PMC6996053.
    • Abskharon R, Seidler PM, Sawaya MR, Cascio D, Yang TP, Philipp S, Williams CK, Newell KL, Ghetti B, DeTure MA, Dickson DW, Vinters HV, Felgner PL, Nakajima R, Glabe CG, Eisenberg DS. Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease. J Biol Chem. 2020 Jul 31;295(31):10662-10676. doi: 10.1074/jbc.RA120.013638. Epub 2020 Jun 3. PMID: 32493775; PMCID: PMC7397112.

Top

Health Professionals